Related Experiment Videos
Multistage designs for phase II clinical trials: statistical issues in cancer research
1Département de biostatistique et d'épidémiologie, Institut Gustave Roussy, Villejuif, France.
Abstract:
The main objective of phase II clinical trials is to estimate treatment efficacy on a relatively small number of patients in order to decide whether the treatment ought to be studied in large-scale comparative trials. They play a key role in the drug development process, since the results determine whether or not to proceed to phase III trials. Multistage designs for phase II clinical trials proposed by Gehan, Fleming, Simon and Ensign are described and compared. Gehan's and Simon's designs have two stages, Fleming's designs can have two or more stages, and Ensign's three-stage design combines the first stage of Gehan with the two stages of Simon. Phase II clinical trial protocols and reports should include a description of the design selected with a justification for the particular choice. The present practice is very far from this ideal.
Insights
Phase II clinical trials evaluate treatment efficacy in small patient groups to determine progression to larger studies. This research compares multistage designs, crucial for guiding drug development decisions.
Area of Science:
- Clinical trial design
- Drug development
- Biostatistics
Background:
- Phase II clinical trials are critical for estimating treatment efficacy.
- Results from Phase II trials determine progression to Phase III studies.
- Effective trial design is essential for informed decision-making in drug development.
Purpose of the Study:
- To describe and compare multistage designs for Phase II clinical trials.
- To highlight the importance of design selection and justification in trial protocols.
Main Methods:
- Comparison of multistage designs proposed by Gehan, Fleming, Simon, and Ensign.
- Analysis of design characteristics including number of stages.
Main Results:
- Gehan's and Simon's designs feature two stages.
- Fleming's designs can have two or more stages.
- Ensign's design integrates elements of Gehan's and Simon's designs.
Conclusions:
- Multistage designs offer varied approaches for Phase II trials.
- Current practices often lack explicit design descriptions and justifications.
- Standardizing design reporting is necessary for improved clinical trial conduct.